University of Colorado, Denver

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Colorado, Denver sits in the top decile of US sponsors by registered trial count (#21 of 15,742 sponsors by registered trial count).

1,283 total trials 265 currently recruiting 830 completed early-phase tilt top decile by trial count

University of Colorado, Denver: 1,283 sponsored US clinical trials, 265 recruiting.

University of Colorado, Denver sponsors 1,283 registered US clinical trials on ClinicalTrials.gov, 265 of them currently recruiting, and 830 completed. 121 of these trials are in Phase 3-4 (later-stage) and 245 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 23 trials.

Top-decile sponsor footprint

University of Colorado, Denver ranks in the top decile of sponsors by registered trial count (#21 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 68/100

830 of 908 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,283 total, page 7 of 26

ACTIVE NOT RECRUITING NA

Effectiveness of Engaging in Advance Care Planning Talks (ENACT) Group Visits in Primary Care for Older Adults With and Without Alzheimer's Disease

NCT05421728

ACTIVE NOT RECRUITING Phase 1

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

NCT05089370

ACTIVE NOT RECRUITING

Adherence and Clinical Correlates in Persons With HIV on TAF

NCT05335590

ACTIVE NOT RECRUITING NA

Care Planning Framework in Advanced Cancer (ABC123)

NCT05408507

ACTIVE NOT RECRUITING

Critical Windows in the Development of Asthma Endotypes and Phenotypes in High-Risk Toddlers

NCT05210361

ACTIVE NOT RECRUITING Phase 4

Molecular Endotypes of Chronic Idiopathic Urticaria

NCT04774315

ACTIVE NOT RECRUITING Phase 2

CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

NCT04520685

ACTIVE NOT RECRUITING

Effect of Hormones on Frequency of Headache and Brain Structure and Function in Puberty

NCT05607303

ACTIVE NOT RECRUITING Phase 4

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

NCT05057546

ACTIVE NOT RECRUITING Phase 2

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

NCT04925193

ACTIVE NOT RECRUITING NA

Childhood Obesity Treatment Designed for Low Income and Hispanic Families

NCT05041855

ACTIVE NOT RECRUITING NA

Virtual Exercise Program to Reduce Cancer Related Fatigue

NCT04533165

ACTIVE NOT RECRUITING NA

Daily Caloric Restriction in ADPKD

NCT04907799

ACTIVE NOT RECRUITING

Skeletal Effects of Chronic Night Shift

NCT05091021

ACTIVE NOT RECRUITING NA

Facing Your Fears: Adolescents With ASD and Intellectual Disability

NCT05131425

ACTIVE NOT RECRUITING NA

Effects of Complementary Feeding on Infant Growth and Gut Health

NCT05012930

ACTIVE NOT RECRUITING NA

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

NCT03586414

ACTIVE NOT RECRUITING Phase 2

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

NCT04963283

ACTIVE NOT RECRUITING NA

Comparing Home, Office, and Telehealth Induction for Medication Assisted Treatment for Opioid Use Disorder

NCT04664062

ACTIVE NOT RECRUITING Phase 3

Strategy to Avoid Excessive Oxygen in Major Burn Patients

NCT04534972

ACTIVE NOT RECRUITING NA

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

NCT04550676

ACTIVE NOT RECRUITING NA

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696

ACTIVE NOT RECRUITING

Advancing Prevention of Pulmonary Fibrosis

NCT04564183

ACTIVE NOT RECRUITING NA

Addition of Dehydrated Human Amnion-Chorion Membrane During Scaling and Root Planing

NCT03836378

ACTIVE NOT RECRUITING Phase 3

Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients

NCT04534959

ACTIVE NOT RECRUITING Phase 4

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

NCT04149470

ACTIVE NOT RECRUITING NA

Tendon-Bone Versus All-Soft-Tissue for ACL Reconstruction: A Patient-Blinded Randomized Clinical Trial

NCT04039971

ACTIVE NOT RECRUITING NA

Identification of Best Postoperative Analgesia Method Following a Minimally Invasive Repair of Pectus Excavatum

NCT04211935

ACTIVE NOT RECRUITING Phase 2

Induction FLOT With CROSS CRT for Esophageal Cancer

NCT04028167

ACTIVE NOT RECRUITING Phase 3

Cisplatin Disposition and Kidney Injury

NCT03817970

ACTIVE NOT RECRUITING Early Phase 1

Tocilizumab in Children With ACP

NCT03970226

ACTIVE NOT RECRUITING

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747

ACTIVE NOT RECRUITING

Total Joint Arthroplasty in a Pediatric Population

NCT04294693

ACTIVE NOT RECRUITING

Longitudinal Innate Immunity and Aging Study

NCT03944603

ACTIVE NOT RECRUITING Phase 2

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

NCT03617679

ACTIVE NOT RECRUITING Phase 2

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

NCT03347838

ACTIVE NOT RECRUITING Phase 2

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

NCT03573024

ACTIVE NOT RECRUITING NA

Impact of Sleep Extension in Adolescents

NCT03500458

ACTIVE NOT RECRUITING Phase 1

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

NCT03564873

ACTIVE NOT RECRUITING

Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy

NCT03626350

ACTIVE NOT RECRUITING Phase 2

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

NCT03466294

ACTIVE NOT RECRUITING

Biomarkers of Immune-Related Toxicity

NCT03409016

ACTIVE NOT RECRUITING

Subcortical Oscillations in Human Sleep Dysregulation

NCT03377569

ACTIVE NOT RECRUITING Phase 2

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

NCT02955394

ACTIVE NOT RECRUITING Phase 4

Statin Therapy in Patients With Early Stage ADPKD

NCT03273413

ACTIVE NOT RECRUITING Phase 1

Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma

NCT02774421

ACTIVE NOT RECRUITING Phase 2

Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes

NCT02700386

ACTIVE NOT RECRUITING NA

Reprometabolic Syndrome Mediates Subfertility in Obesity

NCT02653092

ACTIVE NOT RECRUITING

The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis

NCT02389075

ACTIVE NOT RECRUITING

Cerebral Palsy Adult Transition Longitudinal Study

NCT02137005

← Previous Page 7 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 114
Phase 2 131
Phase 3 37
Phase 4 84

What is open in the University of Colorado, Denver pipeline

265 recruiting of 1,283 indexed (21% open); 830 completed (65%).

Phase mix: 121 late (III/IV) vs 245 early (I/II) (early-phase heavy).

Top condition: Obesity (23 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Colorado, Denver: open-pipeline peers nationwide

Peers matched on 1,283 registered trials and 21% open enrollment, not the therapeutic-area sidebar.

University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20%25% Total trials Recruiting share University of Colorado, DenverAstraZenecaUniversity of MichiganUniversity of PittsburghEli Lilly and CompanyCedars-Sinai Medical CenterCraig HospitalW.L.Gore & AssociatesGeorgia Institute of Technology
University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,283 trials (± recruiting share)

Sponsors near 21% open enrollment (± trial volume)

What to do with this University of Colorado, Denver page

1,283 registered trials is a research-attention snapshot, not an endorsement of University of Colorado, Denver or any single study.

  • 265 of University of Colorado, Denver's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Colorado, Denver studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Colorado, Denver pipeline card: 1,283 registered trials from official public datasets.Report a data error.